Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

Jongeneelen, Mandy; Kaszás, Krisztián; Veldman, Daniel; Huizingh, Jeroen; R, van der Vlugt; Schouten, Theo; Zuijdgeest, David; T, Uil; G, van Roey; Guimerà, Núria; Navis, Marjon; Bos, R.; M, le Gars; Sadoff, Jerald C.; Muchene, Leacky; Juraszek, Jarek; Jp, Langedijk; Vogels, Ronald; Custers, Jerome; Schuitemaker, Hanneke; Brandenburg, Boerries

doi:10.1101/2021.07.01.450707

Cited by 46 publications

(44 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data reported here differ somewhat from those reported by Jongeneelen et al who found that Ad26.COV2.S-elicited antibody titers were mostly maintained against the variants 20 . In addition, Alter et al reported a 5-fold decrease in neutralizing antibody titer against Beta and 3.3-fold decrease against the Gamma variant by the sera from Ad26.COV2.S vaccination 21 which were less pronounced than those reported here.…”

Section: Discussioncontrasting

confidence: 99%

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Tada

Zhou

Samanovic

et al. 2021

Preprint

View full text Add to dashboard Cite

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.

show abstract

Section: Discussioncontrasting

confidence: 99%

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Tada

Zhou

Samanovic

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The antibody titers remained stable for at least 71 days besides a 2.6-2.9-fold increase after the second-dose. Spike binding antibodies also variant [133]. In South Africa, D614G and 501Y.V2 strains of coronavirus demonstrated high levels of cross-reactivity in spike-binding assay (n=120) at least 29 days post-vaccination [134].…”

Section: Sinopharm (Inactivated Virus Vaccine)mentioning

confidence: 98%

Counting on COVID-19 vaccine: Insights into the current strategies, progress and future challenges

Kandimalla¹,

Chakraborthy²,

Vallamkondu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus (SARS-CoV-2) in late 2019 and its subsequent substantial spread, produced coronavirus disease 2019 (COVID-19) pandemic worldwide. Given its unprecedented infectivity and pathogenicity, COVID-19 pandemic had a devastating impact on human health and its clinical management. It led to development and speedy trials of several vaccine candidates against SARS-CoV-2 at an exceptional pace; as a result, several COVID-19 vaccines were made commercially available in the 2021 first half. Although, several COVID-19 vaccines showed promising results, crucial in-sights into their epidemiology, protective mechanism and propensity of reinfection are not largely reviewed. In the present report, we provided insights into the prospects of vaccination against COVID-19 and assessed diverse vaccination strategies including DNA, mRNA, protein subunits, vector-based, live attenuated, and inactivated whole/viral particle-based vaccines, imi-tating COVID-19 infection. Next, we reviewed major aspects of various available vaccines ap-proved by the WHO and by local administration to use against COVID-19. Moreover, we com-prehensively assessed the success of these approved vaccines and also their untoward effects in-cluding the possibility of reinfection. We also provided an update on the vaccines that are under development and could be the promising candidate. Conclusively, we provided insights into the COVID-19 vaccine epidemiology, their potency and propensity for SARS-CoV-2 reinfection, while a careful review of their current status, strategies, success and future challenges was also presented.

show abstract

“…However, these two studies support the notion that following completion of the second dose of vaccination, all the approved vaccines may induce cross-neutralization of at least some of the circulating SARS-CoV-2 variants. It has been showed that the single-shot Ad26.COV2.S is effective against the rapidly spreading Delta variant and other VOC (Jongeneelen et al, 2021). Although the VE of BNT162b2 and ChAdOx1 has been compared against Alpha and Delta variants showing similar efficacy (Stowe et al, 2021), there is no single study comparing the VE of all vaccines so far approved by the WHO against all VOC and VOI.…”

Section: Covid-19 Vaccines Against Sars-cov-2 Variantsmentioning

confidence: 99%

Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges

Hakim

Hasan

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), a pandemic declared by the World Health Organization on March 11, 2020, is caused by the infection of highly transmissible species of a novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As of July 25, 2021, there are 194,372,584 cases and 4,167,937 deaths with high variability in clinical manifestations, disease burden, and post-disease complications among different people around the globe. Overall, COVID-19 is manifested as mild to moderate in almost 90% of the cases and only the rest 10% of the cases need hospitalization. However, patients with older age and those having different comorbidities have made worst the pandemic scenario. The variability of pathological consequences and clinical manifestations of COVID-19 is associated with differential host–SARS-CoV-2 interactions, which are influenced by the factors that originated from the SARS-CoV-2 and the host. These factors usually include the genomic attributes and virulent factors of the SARS-CoV-2, the burden of coinfection with other viruses and bacteria, age and gender of the individuals, different comorbidities, immune suppressions/deficiency, genotypes of major histocompatibility complex, and blood group antigens and antibodies. We herein retrieved and reviewed literatures from PubMed, Scopus, and Google relevant to clinical complications and pathogenesis of COVID-19 among people of different age, sex, and geographical locations; genomic characteristics of SARS-CoV-2 including its variants, host response under different variables, and comorbidities to summarize the dynamics of the host response to SARS-CoV-2 infection; and host response toward approved vaccines and treatment strategies against COVID-19. After reviewing a large number of published articles covering different aspects of host response to SARS-CoV-2, it is clear that one aspect from one region is not working with the scenario same to others, as studies have been done separately with a very small number of cases from a particular area/region of a country. Importantly, to combat such a pandemic as COVID-19, a conclusive understanding of the disease dynamics is required. This review emphasizes on the identification of the factors influencing the dynamics of host responses to SARS-CoV-2 and offers a future perspective to explore the molecular insights of COVID-19.

show abstract

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

Cited by 46 publications

References 7 publications

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Counting on COVID-19 vaccine: Insights into the current strategies, progress and future challenges

Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges

Contact Info

Product

Resources

About